In conclusion, we have shown a promising combination therapy with afatinib and bevacizumab in an EGFR-mutated NSCLC patient with ERBB2 amplification who had acquired resistance to gefitinib therapy. Here, EGFR is linked to non-small cell lung carcinoma.